Nicholas Vogelzang, MD, FASCO, FACP | Perspective on Cancer Care in the Time of COVID-19

ASCO NEWS - Giants of Cancer Care Induction Interview w/ Dr. Vogelzang, MD, FASCO, FACPПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugsПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Addressing Patients on Cancer Care in the Time of COVID-19Подробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPCПодробнее

2020 Cancer Care in the Time of COVID-19 | Patient PerspectiveПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPCПодробнее

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPCПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus XtandiПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPCПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 testПодробнее

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithmsПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticalsПодробнее